Danish drug maker Novo Nordisk said on Wednesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. ...

Core Insights - Pfizer reported fourth-quarter 2025 adjusted earnings per share of 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, with a year-over-year earnings increase of 5% [1] - Total revenues for the quarter were $17.6 billion, a decline of 1% year-over-year on a reported basis and 3% on an operational basis, primarily due to decreased revenues from COVID-19 products [2] Revenue Breakdown - International revenues decreased by 4% on an operational basis to $8.44 billion, while U.S. revenues fell by 1% to $9.1 billion [2] - The Primary Care segment saw a 13% operational decline in sales to $7.94 billion, while Specialty Care recorded a 6% increase to $4.77 billion, and Oncology sales rose by 8% to $4.44 billion [3] Product Performance - Eliquis sales in Primary Care rose by 8% to $2.02 billion, although alliance revenues fell short of the Zacks Consensus Estimate of $2.14 billion [4] - Global revenues from the Prevnar family increased by 8% to $1.71 billion, surpassing the Zacks Consensus Estimate of $1.65 billion [5] - Comirnaty sales were $2.27 billion, down 35% year-over-year, but still beat the Zacks Consensus Estimate of $2.0 billion [6] - Paxlovid revenues dropped by 70% year-over-year to $218 million, missing the Zacks Consensus Estimate of $289 million [7] Full-Year Results - For the full year 2025, Pfizer's sales declined by 2% to $62.6 billion, exceeding the Zacks Consensus Estimate of $61.94 billion [14] - Adjusted earnings for 2025 were $3.22 per share, a 4% increase year-over-year, beating the Zacks Consensus Estimate of $3.13 [14] 2026 Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and an impending patent cliff [16] - COVID sales are projected to be around $5 billion in 2026, down from approximately $6.7 billion in 2025 [17] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80-$3.00, a decrease from 2025's EPS of $3.22 [17] Research and Development - Pfizer plans to initiate 20 pivotal studies in 2026, including 10 for ultra-long-acting obesity candidates from the Metsera acquisition [26] - Positive top-line data from a phase IIb study on PF-08653944 showed significant weight reduction, positioning Pfizer competitively against other weight loss therapies [20][21]

Key Takeaways IQV is set to report Q4 results on Feb. 5, with revenues expected at $4.2B and EPS of $3.40, up 9% y/y.IQV TAS and R&D units will likely rise 6.9% and 7.7%, respectively, on drug launches and a solid RFP pipeline.IQV's geographic growth outlook indicates y/y Asia-Pacific revenue growth of 9.4% to $882.6M.IQVIA Holdings Inc. (IQV) is set to release fourth-quarter 2025 results on Feb. 5, before market open.IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%. https://t.co/HP6jn6TMbw ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%. ...

Novo Nordisk's U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit.The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning. Novo's American depositary shares fell 11% as of 12:05 pm ET. The results were published after the closing bell in Copenhagen, where the company has its primary listing.Its forecast comes as the Danish drugmaker is fighting to regain ...

Pfizer Stock Dives On Modest Guidance, Obesity Update; Can It Catch Eli Lilly? | Investor's Business DailyBREAKING: [Stocks Edge Higher As Teradyne, Palantir Surge]---Pfizer (PFE) stock toppled Tuesday after the S&P health giant reaffirmed its modest outlook for 2026 despite easily beating Wall Street's fourth- quarter expectations. The company also provided an update on its obesity treatment, MET-097i, saying patients who tested a weekly dose for 12 weeks followed by monthly doses up to 28 weeks lost, on a ...

Core Insights - Axsome Therapeutics has shown significant market performance over the past five years, driven by clinical and regulatory advancements, and is approaching large-cap status [1] - There remains potential for further investment in Axsome Therapeutics due to ongoing growth and new product developments [1] Group 1: Sales Growth - Axsome's revenue for the third quarter reached $171 million, reflecting a 63% increase compared to the same period last year [2] - The company's current product lineup includes Auvelity for depression, Sunosi for narcolepsy-related daytime sleepiness, and Symbravo for migraines, all contributing to strong sales growth [2][3] Group 2: Future Approvals - Axsome is pursuing new approvals and label expansions, including a new indication for Auvelity in treating Alzheimer's disease agitation, which has shown positive results in phase 3 studies and is under FDA consideration [4] - Sunosi has completed a phase 3 study for ADHD in adults, with plans for additional late-stage trials in related markets [5] Group 3: New Product Pipeline - The company is developing several other products, such as AXS-12 for cataplexy in narcolepsy and AXS-14 for fibromyalgia, which could significantly enhance sales potential [6] - The addressable market for Alzheimer's agitation is substantial, with over 5 million patients in the U.S. and currently only one FDA-approved treatment available [7]

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts. ...

Novo Nordisk A/S shares plunged after the company shocked investors by forecasting a steep decline in sales, evidence of an intensifying price war in obesity drugs. Sales will fall by as much as 13% this year, the company said Tuesday. Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government’s push to cut prices, will contribute to the decline. Most Read from Bloomberg “It really paints a picture of a challenged Novo,” Lars Hytting, head of trading at ArthaScop ...